Table II.
Association between GLTSCR1 expression and clinicopathological characteristics in patients with prostate cancer.
| TMA (Pearson's χ2 tests) | TCGA (Student's t-tests) | ||||||
|---|---|---|---|---|---|---|---|
| Clinical features | Cases | Low, n (%) | High, n (%) | P-value | Cases | Mean ± SD | P-value |
| Tissue type | |||||||
| Prostate cancer | 73 | 26 (35.6) | 47 (64.4) | 0.015a | 499 | 447.7±6.45 | <0.001b |
| Benign | 7 | 6 (85.7) | 1 (14.3) | 52 | 343.5±14.21 | ||
| Age | |||||||
| <66 | 24 | 11 (45.8) | 13 (54.2) | 0.202 | 354 | 453.79±146.85 | 0.111 |
| ≥66 | 49 | 15 (30.6) | 34 (69.4) | 143 | 431.08±135.44 | ||
| PSA level (ng/ml) | |||||||
| ≤4 | na | na | na | na | 413 | 446.73±143.75 | 0.723 |
| >4 | na | na | na | 27 | 456.83±135.92 | ||
| Gleason score | |||||||
| <7 | na | na | na | na | 44 | 427.34±114.67 | <0.001b |
| =7 | na | na | na | 247 | 419.46±128.84 | ||
| >7 | na | na | na | 206 | 484.84±158.06 | ||
| Pathological grade | |||||||
| ≤2 | 23 | 6 (26.1) | 17 (73.9) | 0.304 | na | na | na |
| >2 | 44 | 17 (38.6) | 27 (61.4) | na | na | ||
| Clinical stage | |||||||
| I–II | 45 | 24 (53.3) | 21 (46.7) | <0.001b | na | na | na |
| III–IV | 27 | 2 (7.4) | 25 (92.6) | na | na | ||
| Tumor invasion | |||||||
| T1-T2 | 48 | 23 (47.9) | 25 (52.1) | 0.003b | 177 (T1) | 437.32±131.93 | 0.011a |
| T3-T4 | 24 | 3 (12.5) | 21 (87.5) | 229 (T2-T4) | 474.09±152.16 | ||
| Lymph node metastasis | |||||||
| N0 | 60 | 26 (43.3) | 34 (56.7) | 0.003b | 344 | 440.49±139.44 | 0.001b |
| N1 | 12 | 0 (0.0) | 12 (100.0) | 80 | 503.48±174.50 | ||
| Distant metastasis | |||||||
| M0 | 58 | 26 (44.8) | 32 (55.2) | 0.001b | 455 | 448.68±141.05 | 0.002b |
| M1 | 14 | 0 (0.0) | 14 (100.0) | 3 | 710.18±381.93 | ||
a
P<0.05
b
P<0.01. GLTSCR1, Glioma Tumor Suppressor Candidate Region Gene 1; PSA, prostate-specific antigen; TCGA, the Cancer Genome Atlas; na, not applicable; T, tumor; N, node; M, metastasis; SD, standard deviation.